Inflammatory Bowel Diseases最新文献

{"title":"hsa_circ_0015388 Reduces Macrophage Derived Reactive Oxygen Species in Crohn's Disease.","authors":"Yuya Sugiyama, Hiroaki Konishi, Tatsuya Dokoshi, Hiroki Tanaka, Yu Kobayashi, Takahiro Sasaki, Koji Yamamoto, Aki Sakatani, Keitaro Takahashi, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Hiroki Tanabe, Toshikatsu Okumura, Mikihiro Fujiya","doi":"10.1093/ibd/izae317","DOIUrl":"10.1093/ibd/izae317","url":null,"abstract":"<p><strong>Background: </strong>Crohn's disease (CD) is a refractory inflammatory bowel disease with an unclear etiology. CircularRNA (circRNA) has been highlighted as a novel class of functional noncoding RNAs associated with the pathogenesis of various diseases. However, the functions of circRNA in CD remain unclear.</p><p><strong>Methods: </strong>Biopsies were obtained from noninflammatory sites in the terminal ileum of the CD group (n = 4) and non-CD group (n = 4) and analyzed for circRNA expression using RNA sequencing. The significantly altered circRNAs were validated in the CD group (n = 45) and non-CD group (n = 15) using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). Transcriptome analysis was conducted using circRNA-downregulated macrophage-like THP-1 cells. Reactive oxygen species (ROS) levels, cytokine mRNA expression, phagocytosis, and migration were evaluated in circRNA-downregulated THP-1 cells.</p><p><strong>Results: </strong>CircularRNA sequencing analysis revealed significant differences in 31 circRNAs between the CD group and non-CD group. Quantitative reverse transcriptase-polymerase chain reaction analysis for each circRNA demonstrated significant upregulation of hsa_circ_0015388 in the CD group. Hsa_circ_0015388 was expressed in THP-1 cells, but not in HCEC-1CT and Caco-2/bbe. Transcriptome analysis in THP-1 cells transfected with scramble or hsa_circ_0015388 siRNA (small interfering RNA) showed a significant alteration in innate immune response related pathway. Reactive oxygen species production was significantly increased in the hsa_circ_0015388 downregulated THP-1 cells. Reactive oxygen species induction in the hsa_circ_0015388 knocked down THP-1 was diminished by the inhibition of TNFSF10.</p><p><strong>Conclusion: </strong>A comprehensive analysis of circRNA expression revealed that 31 circRNAs were dysregulated in the CD group. Hsa_circ_0015388 is expressed in macrophages and negatively regulates ROS function inhibiting the TNFSF10 pathway. This study first revealed that hsa_circ_0015388 plays a role in the pathogenesis of CD by suppressing ROS production in macrophages.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1355-1365"},"PeriodicalIF":4.5,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142978368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Review: Practices and Programs in Inflammatory Bowel Disease Transition Care.","authors":"Patrick Chan, Jack McNamara, Angharad Vernon-Roberts, Edward M Giles, Rachael Havrlant, Britt Christensen, Amanda Thomas, Astrid-Jane Williams","doi":"10.1093/ibd/izae190","DOIUrl":"10.1093/ibd/izae190","url":null,"abstract":"<p><strong>Background: </strong>Adolescents with inflammatory bowel disease (IBD) transitioning to adult care is often deemed a challenging period for patients, their carers, and practitioners. The use of structured transition programs is increasingly incorporated into standards of care, yet the optimal format remains unknown. The aim of this study is to carry out a systematic review of structured transition programs and their components to assess the impact on disease-specific and transition-related outcomes.</p><p><strong>Methods: </strong>A systematic review (PROSPERO ID: CRD42023380846) was performed across 4 databases (PubMed, CINAHL, CENTRAL, and EMBASE) and relevant publications up to March 2023 were reviewed. Studies evaluating either a structured transition program or targeted intervention which also measured a transition- and/or disease-related outcomes were included for evaluation in accordance with the PRISMA statement.</p><p><strong>Results: </strong>Three thousand four hundred and thirty-two articles were identified and 29 included in the final review. A structured transition program was reported in 21 studies and 8 investigated discrete transition-related interventions. The key transition-related outcomes included knowledge, self-efficacy, adherence, clinic attendance, and transition readiness which overall improved with the use of structured transition programs. Similarly, interventions consistently improved relapse/admission rates and corticosteroid use across most studies, although the benefit in hospitalization and surgical rates was less evident. Methodological limitations alongside heterogeneity in study design and outcome measures impacted on the quality of the evidence as assessed by the GRADE rating.</p><p><strong>Conclusions: </strong>Transition- and medical-related outcomes for adolescents with IBD have been shown to benefit from structured transition programs but practices vary greatly between centers. There is no current standardized transition model for patients with IBD prompting further research to guide future development of guidelines and models of care.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1404-1418"},"PeriodicalIF":4.5,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142086021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How Does an Integrated Pharmacist Add Value in the Management of Inflammatory Bowel Disease in the Era of Values-Based Healthcare?","authors":"Patrick Hilley, Darren Wong, Peter De Cruz","doi":"10.1093/ibd/izae196","DOIUrl":"10.1093/ibd/izae196","url":null,"abstract":"<p><p>The World Health Organization has recommended that the management of chronic diseases such as inflammatory bowel disease (IBD) should be undertaken using an integrated approach delivered by a multidisciplinary team. Although the composition of an IBD multidisciplinary team has been well described, the inclusion of an IBD pharmacist as a core member has been more recent, with variable uptake within IBD services internationally. While pharmacists continue to play the traditional role of safe prescribing and monitoring of immunosuppressive therapies, their role within the IBD team is rapidly expanding; however, the value, in terms of both clinical outcomes as well as financial savings (where available), which they add to IBD services has been less well described. In this narrative review, we perform a comprehensive evaluation of the literature detailing the expanding roles that IBD pharmacists play and describe opportunities that exist for integrated pharmacists to add value to IBD service delivery. Medication and adherence counseling, immunosuppressive monitoring, uptake of biosimilars, therapeutic drug monitoring, health promotion and prevention appear to be key areas where integrated pharmacists can add the most value to IBD patients and services. In particular, integrated IBD pharmacists can improve patient outcomes via rigorous monitoring pre and post initiation of drug therapies; focused medication counseling; advice on improving adherence; implementation of novel approaches to medication usage, and; strategies to help sustain IBD service delivery. These data can be used to further build a case for those seeking to add pharmacists to their team/services. Future studies should focus on evaluating the impact of an integrated IBD pharmacist on quality-of-care delivery together with the clinical and financial value added to IBD services compared to services that lack an integrated IBD pharmacist role.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1419-1429"},"PeriodicalIF":4.5,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142107002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18F-FAPI PET/CT for Early Detection and Severity Assessment of Intestinal Fibrosis in a Mouse Model.","authors":"Weicheng Zhou, Jiantao Ran, Xinyue Hu, Chaoqun Lv, Jianping You, Duo Sun, Leiyue Chen, Yi Tang, Hongqing Li, Daoxi Hu, Kaijun Liu, Dongfeng Chen, Xiao Chen","doi":"10.1093/ibd/izaf086","DOIUrl":"https://doi.org/10.1093/ibd/izaf086","url":null,"abstract":"<p><strong>Background: </strong>To investigate the feasibility of using 18F-fibroblast activation protein (FAP) inhibitor positron emission tomography/computed tomography (18F-FAPI PET/CT) to detect intestinal fibrosis in its early stages and identify its severity in a mouse model.</p><p><strong>Methods: </strong>A dextran sulfate sodium (DSS)-induced mouse model of intestinal fibrosis was established. To detect pro-inflammatory cytokines and histopathology, blood and intestinal lesion samples were collected after 18F-FAPI PET/CT scanning (3.7 MBq/mice) at 3, 6, 9, and 12 weeks post-initial exposure to DSS. Correlation and diagnostic efficacy were explored between 18F-FAPI uptake and FAP expression or fibrosis score in early, late, and entire stages of intestinal fibrosis.</p><p><strong>Results: </strong>18F-FAPI uptake was positively correlated with FAP expression throughout entire stages of intestinal fibrosis (r = 0.90). However, a weak correlation between 18F-FAPI uptake and fibrosis score (r = 0.49), and moderate diagnostic performance of 18F-FAPI PET for fibrotic severity (area under the receiver-operating characteristic curve [AUC] = 0.79) were found throughout the entire stages. Interestingly, in the early stages, 18F-FAPI PET effectively distinguished the degree of intestinal fibrosis (AUC = 0.95), and was strongly correlated with fibrosis score (r = 0.89). In the late stages, the diagnostic efficacy (AUC = 0.46) and correlation (r = -0.20) drastically decreased.</p><p><strong>Conclusions: </strong>As Crohn's disease (CD) with intestinal fibrosis progresses, 18F-FAPI uptake is high in the early stages and then gradually decreases. Activated fibroblasts appear more frequently in the early stages of intestinal fibrosis indicates that 18F-FAPI PET has a great potential for early identification of intestinal fibrosis and provides new insights into treatment decision-making in CD patients.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innate and Adaptive Immunity is not Impacted by Inflammatory Bowel Disease Medications in Pregnant Women and Their Offspring.","authors":"Ralley E Prentice, Steven X Cho, Sally J Bell, Claudia A Nold-Petry, Marie Lee, Indiana Zorkau, Megan Burns, Emily K Wright, Emma Flanagan, Marcel F Nold, Rimma Goldberg","doi":"10.1093/ibd/izaf052","DOIUrl":"https://doi.org/10.1093/ibd/izaf052","url":null,"abstract":"<p><strong>Background and aims: </strong>Inflammatory bowel disease (IBD) therapeutics and pregnancy itself are known to impact immune cell populations, but a detailed understanding of the effect of specific therapies is lacking, particularly for infants exposed in utero. With comprehensive flow cytometric assessment, we aimed to explore how IBD and its treatment impact both maternal and infant immunophenotypes and cytokine production.</p><p><strong>Methods: </strong>Peripheral blood was taken for flow cytometry immunophenotyping and quantification of cytokine responses to stimulation from women with IBD and healthy controls throughout pregnancy, at delivery, and postpartum. Blood samples were also taken from the umbilical cord and peripherally from the resultant offspring at the age of 6 weeks.</p><p><strong>Results: </strong>Eighteen participants (16 with IBD and 2 healthy controls) were recruited to this single-center prospective cohort study. Basal T regulatory cell population proportions were 46% lower (0.21% vs 0.39%, P = .027) in those participants exposed to ustekinumab (n = 4). No other significant differences were noted in immunophenotype according to drug therapy exposure. Basal (1.75% vs 0.47%, P = .036) and lipopolysaccharide-stimulated (72.2% vs 64.7%, P = .028) production of tumour necrosis factor by classical dendritic cells were increased 3.7- and 1.1-fold, respectively, in those with an elevated fecal calprotectin (n = 6). Basal CD4+α4β7+ (41.4% to 66.5%, P = .0043) and CD8+α4β7+ (81.2% to 93.6%, P = .007) population proportions increased 1.6- and 1.2-fold, respectively, in infants from birth to 6 weeks.</p><p><strong>Conclusions: </strong>This study provides the foundation for ongoing investigation to more definitively extricate the impact of maternal IBD activity, drug exposures, and disease phenotype on infant immune system development and function. These novel data suggest that IBD pharmacotherapies may not significantly impact maternal or infant immune regulation.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal Microchimerism, a Red Flag or a Red Herring in Very-Early-Onset Inflammatory Bowel Disease?","authors":"Sachith Munasinghe, Shanmuganathan Chandrakasan","doi":"10.1093/ibd/izaf070","DOIUrl":"https://doi.org/10.1093/ibd/izaf070","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Venous Thromboembolism in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis by Phase of Care.","authors":"Michal Gozdzik, Dana Unninayar, Deborah M Siegal, Avijeet Kumar Sarker, Eileen Kim, Sanjay Murthy, Eric I Benchimol, Geoffrey C Nguyen, Jeffrey D McCurdy","doi":"10.1093/ibd/izaf078","DOIUrl":"https://doi.org/10.1093/ibd/izaf078","url":null,"abstract":"<p><strong>Background: </strong>Risk factors for venous thromboembolism (VTE) and their relative magnitudes across different phases of care in inflammatory bowel disease (IBD) are poorly understood. Therefore, we performed a systematic review to identify risk factors for VTE in patients with IBD during the hospitalized, post-operative, post-discharge, and ambulatory phases of care.</p><p><strong>Methods: </strong>MEDLINE, EMBASE, and Cochrane CENTRAL were systematically searched from inception through to April 2024 without language restriction. We included studies that reported risk factors for VTE among adults with IBD. Summary estimates with 95% confidence intervals (CIs) were calculated for individual risk factors overall and stratified by phase of care using random effects models.</p><p><strong>Results: </strong>A total of 123 studies with over 23 510 969 patients were analyzed. We identified 48 variables for meta-analysis overall and 27 were significantly associated with VTE. The strongest risk factors were prior VTE (odds ratio [OR], 4.44; 95% CI, 2.63-7.49), surgical complications (OR, 3.06; 95% CI, 2.48-3.77), urgent surgery (OR, 2.33; 95% CI, 1.62-3.35), blood transfusions (OR, 2.68; 95% CI, 1.17-6.12), hypoalbuminemia (OR, 2.25; 95% CI, 1.93-2.62), and total parenteral nutrition (OR, 2.21; 95% CI, 1.85-2.64). Corticosteroids (OR, 1.60; 95% CI, 1.46-1.76) but not anti-tumor necrosis factor therapy (OR, 0.66; 95% CI, 0.46-0.97) were associated with an increased risk of VTE. No major differences were observed for most variables between hospitalized, post-operative, and post-discharge settings.</p><p><strong>Conclusions: </strong>We identified multiple risk factors associated with VTE across different phases of care. This work will help in the development of future predictive models to guide thromboprophylaxis in IBD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Past But Not Forgotten: Innate Factors Affect the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease.","authors":"Georgios Kokkotis, Giorgos Bamias","doi":"10.1093/ibd/izaf105","DOIUrl":"https://doi.org/10.1093/ibd/izaf105","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in Access and Treatment for Rural Patients With Inflammatory Bowel Disease: A Survey of Inflammatory Bowel Disease Patients and Providers.","authors":"Timothy McAuliffe, Jessica K Salwen-Deremer, Corey A Siegel","doi":"10.1093/ibd/izaf090","DOIUrl":"https://doi.org/10.1093/ibd/izaf090","url":null,"abstract":"<p><strong>Background: </strong>With the increasing complexity of inflammatory bowel disease (IBD) care, the integration of IBD specialist gastroenterologists and multidisciplinary teams (MDTs) is becoming more important. However, access to these services is not widely available. This study sought to evaluate the needs of rural and urban IBD patients and providers in the setting of complex IBD care.</p><p><strong>Methods: </strong>Questionnaires were administered to IBD patients, advanced practice providers (APPs), and gastroenterologists throughout the United States from September through November 2023 on topics including access to care, IBD specialists, and MDTs. Statistical analyses included t-tests, chi-square tests, analysis of variance tests, and regression.</p><p><strong>Results: </strong>The analysis included 100 rural and 100 urban patients, 20 rural and 50 urban APPs, and 35 rural and 50 urban gastroenterologists. Rural patients were more likely to be receiving no therapy for IBD and less likely to receive advanced therapies (P = .001, P < .001, respectively). Rural patients reported less use of IBD multidisciplinary care and providers identified reduced access to multidisciplinary providers for rural patients. All patients had high interest in maintaining relationships with their current IBD provider while receiving care through a consulting MDT. Providers expressed strong interest in MDTs, with rural gastroenterologists reporting greater interest than urban gastroenterologists (P = .004).</p><p><strong>Conclusions: </strong>These results demonstrate disparities between rural and urban patients' treatments and access to specialty IBD care. Rural patients and providers are supportive of collaborating with IBD specialists and MDTs. These results can help guide the implementation of innovative IBD care models in the setting of an increasingly complex IBD landscape.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-Assisted IBD Severity Classification: A Critical Perspective on Current Evidence and Next Steps.","authors":"Shubham Kumar, Rachana Mehta, Ranjana Sah","doi":"10.1093/ibd/izaf103","DOIUrl":"https://doi.org/10.1093/ibd/izaf103","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}